Drugs / PF-07209326
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04255875 | Feb 2020 → Jul 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07209326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04255875 ↗ |
| Route | Subcutaneous | “PF-07209326 delivered by subcutaneous injection” NCT04255875 ↗ |